Gluco-A100 mg

Gluco-A is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is used to reduce post-prandial (after-meal) blood glucose spikes by delaying the digestion and absorption of complex carbohydrates.

• Monotherapy: When diet and exercise alone are insufficient to control blood glucose.
• Combination therapy: May be added to a sulfonylurea, metformin, or insulin when a single agent does not provide adequate glycemic control; combination use requires dose adjustment and monitoring for hypoglycemia.
• Off-label/adjunctive use: Sometimes used off-label as adjunctive therapy in type 1 diabetes to reduce post-prandial glucose excursions, at the discretion of the treating physician.

Gluco-A is not indicated for the treatment of type 1 diabetes as a sole agent or for diabetic ketoacidosis.

Each tablet of Acarbose contains Acarbose USP/BP as the active ingredient. It is commonly available in strengths of 25 mg, 50 mg, and 100 mg oral tablets, along with pharmaceutical excipients required for tablet formulation.

Gluco-A is an oral anti-diabetic medicine belonging to the alpha-glucosidase inhibitor class. It works locally within the small intestine to slow the breakdown of complex carbohydrates and sucrose into absorbable simple sugars, thereby blunting the rise in blood glucose that normally follows a meal. Less than 2% of an oral dose is absorbed as active drug, so its principal action is local, within the gut.

Gluco-A is used alongside diet and exercise, and sometimes together with other anti-diabetic medicines, to help people with type 2 diabetes mellitus achieve better overall blood glucose control.

Gluco-A belongs to the alpha-glucosidase inhibitor class of oral anti-diabetic (anti-hyperglycemic) medicines.

Mechanism of Action

Acarbose competitively and reversibly inhibits intestinal brush-border alpha-glucosidase enzymes (glucoamylase, sucrase, maltase, and isomaltase) and, to a lesser extent, pancreatic alpha-amylase. These enzymes are normally responsible for breaking down complex carbohydrates and disaccharides (such as sucrose) into absorbable monosaccharides.

By delaying this enzymatic breakdown, Acarbose slows the digestion and absorption of dietary carbohydrates, which reduces and delays the rise in blood glucose that occurs after meals, without stimulating insulin release.

Pharmacokinetics

Less than 2% of an oral dose of Acarbose is absorbed as the active parent compound; the remainder acts locally within the gastrointestinal tract or is degraded by intestinal bacteria and digestive enzymes and eventually eliminated, largely in the feces. Because systemic absorption is minimal, Acarbose does not itself cause hypoglycemia when used alone.

Gluco-A tablets should be swallowed whole or chewed with the first bite of each main meal (breakfast, lunch, and dinner as applicable). Taking Gluco-A at any other time, or skipping a meal after taking a dose, reduces its effectiveness and may increase the risk of gastrointestinal side effects. Doses should not be doubled if a dose is missed with a meal.

Clinically Significant Interactions

• Insulin and sulfonylureas: Concomitant use increases the risk of hypoglycemia. If hypoglycemia occurs, it must be treated with oral glucose (dextrose), not sucrose, because Gluco-A delays sucrose digestion.
• Digestive enzyme preparations (e.g., amylase, pancreatin): May reduce the effect of Gluco-A and should generally be avoided during concurrent use.
• Intestinal adsorbents (e.g., activated charcoal) and some digestive enzyme preparations: May reduce the efficacy of Gluco-A.
• Digoxin: Concomitant administration with Gluco-A may require an adjustment of digoxin dose; serum digoxin levels should be monitored when therapy is started or stopped.

Patients should inform their physician of all medicines, including over-the-counter drugs and herbal products, before starting Gluco-A.

Common Side Effects

Gastrointestinal effects are the most frequently reported, are related to undigested carbohydrate fermentation in the colon, and often lessen with continued use:

• Flatulence (very common)
• Abdominal pain/bloating or distension
• Diarrhea

Less Common but Important Effects

• Elevated liver transaminases, particularly with high doses (rare, usually reversible on discontinuation) - see Precautions and Warnings.
• Skin reactions (rash, urticaria) - rare.

Gluco-A alone does not typically cause hypoglycemia; hypoglycemia risk arises mainly when combined with insulin or sulfonylureas (see Interactions).

Pregnancy

Gluco-A is not generally recommended for glycemic control during pregnancy; insulin is typically preferred by treating physicians to achieve tight glycemic control in pregnancy. Gluco-A should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician must be consulted before use in pregnancy.

Lactation

It is not well established whether Gluco-A or its metabolites are excreted in human breast milk. Because systemic absorption of Gluco-A is minimal, risk to a nursing infant is expected to be low, but caution is advised and a physician should be consulted before use of Gluco-A during breastfeeding.

Hepatic Monitoring

Rare cases of elevated serum transaminases and hepatotoxicity have been reported, particularly with doses above 50 mg three times daily. Periodic monitoring of liver enzymes is reasonable, especially during the first 6-12 months of therapy with Gluco-A.

Gastrointestinal Conditions

Gluco-A should be used with caution in patients with a history of partial intestinal obstruction, abdominal surgery, or conditions predisposed to worsen with excess intestinal gas; in more severe cases these are absolute contraindications (see Contraindications).

Renal Impairment

Gluco-A is contraindicated in severe renal impairment; use with caution and monitor in mild-to-moderate renal impairment.

Hypoglycemia in Combination Therapy

When used with insulin or a sulfonylurea, hypoglycemia may occur; it must be treated with oral glucose rather than sucrose (see Interactions).

Loss of Glycemic Control

When patients are exposed to stress such as fever, trauma, infection, or surgery, temporary loss of glycemic control may occur; a physician may need to adjust therapy, including temporary use of insulin.

Overdose of Gluco-A taken alone (without insulin or a sulfonylurea) is not expected to cause hypoglycemia, but may cause increased gastrointestinal symptoms such as flatulence, abdominal bloating, and diarrhea, which are typically transient. Ingestion of food or drinks containing carbohydrates around the time of an overdose should be avoided, as these will not be well absorbed. If overdose occurs in combination with insulin or a sulfonylurea, hypoglycemia may result. In case of a suspected overdose, seek immediate medical attention or contact emergency services/poison control; do not attempt unsupervised home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Safety and efficacy of Gluco-A in pediatric patients have not been established; its use is generally not recommended in children.

Elderly Use

No overall differences in safety or effectiveness have been observed between elderly and younger adult patients, but dose titration should be cautious given the greater likelihood of decreased renal or hepatic function in this age group.

Renal Impairment

Contraindicated in severe renal impairment (creatinine clearance less than 25 mL/min); see Contraindications.

Hepatic Impairment

Contraindicated in cirrhosis; periodic liver function monitoring is advised in patients on long-term therapy (see Precautions and Warnings).

Gluco-A is generally used long-term as part of ongoing management of type 2 diabetes mellitus, alongside diet and exercise. The duration of therapy is determined by the treating physician based on blood glucose control, HbA1c targets, and tolerability, and is typically continued indefinitely as part of chronic diabetes management unless discontinued due to intolerance or a change in treatment plan.

Alpha-glucosidase inhibitor; oral anti-diabetic (anti-hyperglycemic) agent.

Acarbose reversibly inhibits intestinal alpha-glucosidase enzymes and pancreatic alpha-amylase, delaying the breakdown of complex carbohydrates and sucrose into absorbable glucose. This slows carbohydrate digestion and absorption in the small intestine, reducing the rise in blood glucose after meals without stimulating insulin secretion.

B

Safety and efficacy of Gluco-A have not been established in pediatric patients. Use in children is generally not recommended unless specifically directed by a pediatric specialist.